Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...

On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Wegovy has become a ...

Detailed price information for Moonlake Immunotherapeutics (MLTX-Q) from The Globe and Mail including charting and trades.

LPL Financial LLC ('LPL Financial”), a wholly owned subsidiary of LPL Financial Holdings Inc. (Nasdaq: LPLA) (the 'Company”), today released its monthly activity report for July 2025.

PhD/MPhil Pharmacy and Pharmaceutical Sciences Tackle the biggest challenges in biology, medicine and health in a world leading research environment, and prepare for your future career.

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced that the European Commission (EC) has granted conditional ...